Top

Published in:

01-12-2019 | Macular Degeneration | AdisInsight Report

Brolucizumab: First Approval

Author: Anthony Markham

Published in: Drugs | Issue 18/2019

Abstract

Brolucizumab (Beovu^®) is a low molecular weight, single-chain antibody fragment vascular endothelial growth factor (VEGF) inhibitor being developed by Novartis for the treatment of exudative (wet) age-related macular degeneration (AMD), diabetic macular oedema and macular oedema secondary to retinal vein occlusion. Based primarily on the results of the phase III HAWK and HARRIER trials brolucizumab was recently approved in the US for the treatment of wet AMD. This article summarizes the milestones in the development of brolucizumab leading to this first approval.

Novartis. BEOVU^® (brolucizumab-dbll) injection, for intravitreal injection: US prescribing information. 2019. https://www.pharma.us.novartis.com/sites/, www.pharma.us.novartis.com/files/beovu.pdf. Accessed 11 Nov 2019.

Novartis. Novartis receives FDA approval for BEOVU^®, offering wet AMD patients vision gains and greater fluid reductions vs aflibercept [media release]. 8 Oct 2019. https://www.prnewswire.com.

Alcon. Alcon to acquire Swiss biotechnology firm, ESBATech AG [media release]. 14 Sep 2009. http://www.alcon.com.

Alcon. Alcon and Novartis complete merger and form new Alcon Division to accelerate global leadership in eye care [media release]. 8 Apr 2011. http://www.alcon.com.

Novartis. Novartis continues transformation into a leading medicines company with completion of the Alcon spin-off [media release]. 9 Apr 2019. http://www.novartis.com.

Gaudreault J, Gunde T, Floyd HS, et al. Preclinical pharmacology and safety of ESBA1008, a single-chain antibody fragment, investigated as potential treatment for age related macular degeneration. Invest Ophthalmol Vis Sci. 2012;53(14):3025.

Tietz J, Spohn G, Schmid G, et al. Affinity and potency of RTH258 (ESBA1008), a novel inhibitor of vascular endothelial growth factor a for the treatment of retinal disorders [abstract]. Invest Ophthalmol Vis Sci. 2015;56(7):1501.

Holz FG, Dugel PU, Weissgerber G, et al. Single-chain antibody fragment VEGF inhibitor RTH258 for neovascular age-related macular degeneration: a randomized controlled study. Ophthalmology. 2016;123(5):1080–9.CrossRef

Nimz EL, Van TLCW, Yanez JA, et al. Intraocular and systemic pharmacokinetics of brolucizumab (RTH258) in nonhuman primates [abstract]. Invest Ophthalmol Vis Sci. 2016;57(12):4996.

10.

Dugel PU, Koh A, Ogura Y, et al. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2019. https://doi.org/10.1016/j.ophtha.2019.04.017.CrossRefPubMed

11.

Singh RP, Wykoff CC, Tadayoni R, et al. Visual and expanded anatomical outcomes for brolucizumab versus aflibercept in patients with neovascular AMD: 96-week data from HAWK and HARRIER [abstract]. Investig Ophthalm Vis Sci. 2019;60(9):5194.

12.

Dugel PU, Lang GE, Razavi S, et al. Predictability of the 12-week dosing status at week 48 for patients receiving brolucizumab in HAWK and HARRIER [abstract]. Investig Ophthalm Vis Sci Conf. 2018;59(9):1455.

13.

Dugel PU, Jaffe GJ, Sallstig P, et al. Brolucizumab versus aflibercept in participants with neovascular age-related macular degeneration: a randomized trial. Ophthalmology. 2017;124(9):1296–304.CrossRef

Title: Brolucizumab: First Approval
Author: Anthony Markham
Publication date: 01-12-2019
Publisher: Springer International Publishing
Keywords: Macular Degeneration
Aflibercept
Published in: Drugs / Issue 18/2019
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI: https://doi.org/10.1007/s40265-019-01231-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Brolucizumab: First Approval

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 18/2019

Immune Checkpoint Inhibition in Non-metastatic Non-small Cell Lung Cancer: Chance for Cure?

Dimethyl Fumarate: A Review in Relapsing-Remitting MS

Correction to: Cell-Based Quadrivalent Inactivated Influenza Virus Vaccine (Flucelvax® Tetra/Flucelvax Quadrivalent®): A Review in the Prevention of Influenza

Once-Daily versus Twice-Daily Tacrolimus in Kidney Transplantation: A Systematic Review and Meta-analysis of Observational Studies

Correction to: Dapagliflozin: A Review in Type 2 Diabetes

Acknowledgement to Referees